Helixgate

Helixgate

Uncategorized

STAT+: Trump celebrates closing first round of drug pricing deals, promises more ahead

Published

on

WASHINGTON — President Trump heralded a drug pricing agreement with Regeneron on Thursday, closing the last of 17 deals initially sought by the White House last year.

Regeneron, as part of the private deal, will reduce prices on drugs to Medicaid, provide cholesterol medicine Praluent on TrumpRx for $225, and invest $27 billion in drug development in the United States.

On the same day, Regeneron also announced Food and Drug Administration approval of Otarmeni, the first gene therapy to be greenlit under the agency’s new National Priority Voucher program. In early trials, the drug provided modest hearing gains for people with a rare type of hearing loss, though its development has received pushback from parts of the Deaf community. Regeneron plans to offer the drug at no cost to American patients. 

Continue to STAT+ to read the full story…

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Experts wonder ‘Where is the CDC?’ as hantavirus outbreak unfolds

Published

on

NEW YORK — No quick dispatching of disease investigators. No televised news conference to inform the public. No timely health alerts to doctors.

In the midst of a hantavirus outbreak that involves Americans and is making headlines around the world, the U.S. government’s top public health agency, the Centers for Disease Control and Prevention, has been uncharacteristically missing in action, according to a number of experts.

Read the rest…

Continue Reading

Uncategorized

Opinion: Dr. Glaucomflecken wants the corporatization of medicine to be national news

Below is a lightly edited, AI-generated transcript of the “First Opinion Podcast” interview with Will Flanary, aka Dr. Glaucomflecken. Be sure to sign up for the weekly “First Opinion Podcast” on Apple PodcastsSpotify, or wherever you get your podcasts. Get alerts about each new episode by signing up for the “First Opinion Podcast” newsletter. And don’t forget to sign up for the First Opinion newsletter, delivered every Sunday.

Torie Bosch: Will Flanary is better known as Dr. Glaucomflecken. He is social media’s most famous comedian slash doctor, and he’s not afraid of punching up.

Read the rest…

Read More

Published

on

Below is a lightly edited, AI-generated transcript of the “First Opinion Podcast” interview with Will Flanary, aka Dr. Glaucomflecken. Be sure to sign up for the weekly “First Opinion Podcast” on Apple PodcastsSpotify, or wherever you get your podcasts. Get alerts about each new episode by signing up for the “First Opinion Podcast” newsletter. And don’t forget to sign up for the First Opinion newsletter, delivered every Sunday.

Torie Bosch: Will Flanary is better known as Dr. Glaucomflecken. He is social media’s most famous comedian slash doctor, and he’s not afraid of punching up.

Read the rest…

Read More

Continue Reading

Uncategorized

Biotech’s new company model; The super poop behind a startup launch; and more

Biotech’s new company model; The super poop behind a startup launch; and more

Published

on

Welcome back to another edition of Endpoints Weekly! Earnings season is in full swing, but we had plenty of original reporting and exclusives you won’t find anywhere else this week. Chief among them: Andrew Dunn’s …​ ​Read More

Continue Reading
Advertisement

Trending